Sousa Ben sold $401K of ICUI

Sousa Ben (Chief Information Officer) sold 2,250 shares of ICU MEDICAL INC/DE (ICUI) at $178.32 ($0.40M total) on 2026-08-12.

Original reporting
SEC EDGAR · Sousa Ben
Published Aug 12, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ICUI
Neutral
medium confidence
Mentioned
$ICUI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the company’s CIO, including share count, price, and post-transaction holdings. No company performance, guidance, or corporate action is disclosed.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no fundamental catalyst to drive repricing.

03

What to watch

Insider sales are frequently pre-planned or tax-related; without additional context (other insiders, buybacks, guidance), the signal is weak.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, after-hours disclosure window

Background

The article is a SEC Form 4 insider transaction disclosure for ICU Medical, Inc. (ICUI).

Company-level read

Ticker impact

$ICUINeutralMedium confidence
Context

ICU Medical disclosed a Form 4 showing CIO Sousa Ben sold 2,250 shares at $178.3152 on 2026-08-12 for about $401K.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 insider sales are common and often not predictive; the filing provides transaction details but no new operational, financial, or regulatory information.

Market effects

Minimal; insider selling in a single healthcare equipment name does not reset sector expectations.

None.

None.

Counterpoint

The sale could be routine liquidity or diversification, and the absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • ICU Medical, Inc.

    US-listed company whose insider transaction was reported on Form 4.

  • Sousa Ben

    Chief Information Officer who sold 2,250 shares on 2026-08-12.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICUIHighAI 8/10

ICU Medical (ICUI) Q3 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q3 2026 adjusted EPS of $2.44, up 20% YoY, with adjusted EBITDA at $114M. Revenue growth was driven by consumables (+5%) and IV systems (+11%), while Vital Care declined (-10%). The company expects full-year EBITDA and EPS to be at the higher end of previous guidance.

$ICUIMedAI 8/10

ICU Medical Inc (ICUI) Q3 2026 Earnings Call Highlights: Record Sales, 20% EPS Growth

ICU Medical Inc reported Q3 2026 earnings with 11% growth in Infusion Systems, driven by competitive wins and customer utilization. The company aims for a 43% gross margin by 2027, with potential for earlier achievement. FDA requested additional testing for MedFusion 5,000 syringe pump and ambulatory pump submissions. Management discussed macroeconomic challenges, currency impacts, and strategic initiatives like the Otsuka joint venture.

$ICUIHigh

ICU Medical Q3 Earnings Call Highlights

ICU Medical (ICUI) reported Q3 earnings, noting delayed Infusion Systems volume and revised growth expectations. Vital Care revenue declined 12% due to logistics issues, with full-year decline expected to be larger than anticipated. Adjusted gross margin expanded to 42%, with debt reduction continuing. The company maintained 2026 guidance but lowered capital spending forecasts.

$ICUIHighAI 8/10

ICU Medical: Q3 Earnings Snapshot

ICU Medical Inc. (ICUI) reported Q3 net income of $26.8M, or $1.07 per share, beating estimates. Adjusted EPS was $2.44, and revenue was $560.4M, also exceeding forecasts. The company expects full-year EPS of $8.60-$9.00.